Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have changed practice due to significant improvement in progression free survival (PFS) and overall survival (OS) seen in this disease setting. There is a genuine interest to use SG sequentially after T-DXd, however there is no current prospectively curated evidence to support this strategy. Though

Trial Details

NCT ID
NCT06665178
Phase
PHASE2
Sponsor
British Columbia Cancer Agency
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Sacituzumab Govitecan
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934

Key Eligibility Criteria

  • Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
  • Willing and able to provide signed informed consent approved by UBC/BC Cancer REB
  • Female or male patients, regardless of race and ethnic group, who are ≥18 years old at the time of informed consent
  • Patients with locally advanced or metastatic ER+/HER2 low (defined as IHC 1+ or 2+ but FISH or CISH negative by ratio as per ASCO/CAP guidelines) b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →